Related references
Note: Only part of the references are listed.Synthesis and Biologic Evaluation of a Novel F-18-Labeled Adnectin as a PET Radioligand for Imaging PD-L1 Expression
David J. Donnelly et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
Liposomal nanohybrid cerasomes targeted to PD-L1 enable dual-modality imaging and improve antitumor treatments
Yang Du et al.
CANCER LETTERS (2018)
Practical Immuno-PET Radiotracer Design Considerations for Human Immune Checkpoint Imaging
Aaron T. Mayer et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
In Vivo Imaging of the Programmed Death Ligand 1 by 18F PET
Dinko E. Gonzalez Trotter et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
Nuclear and Fluorescent Labeled PD-1-Liposome-DOX-64Cu/IRDye800CW Allows Improved Breast Tumor Targeted Imaging and Therapy
Yang Du et al.
MOLECULAR PHARMACEUTICS (2017)
ImmunoPET Imaging of CTLA-4 Expression in Mouse Models of Non-small Cell Lung Cancer
Emily B. Ehlerding et al.
MOLECULAR PHARMACEUTICS (2017)
LAG-3+tumor infiltrating lymphocytes in breast cancer: clinical correlates and association with PD-1/PD-L1+tumors
S. Burugu et al.
ANNALS OF ONCOLOGY (2017)
Atezolizumab in metastatic TNBC (mTNBC): Long-term clinical outcomes and biomarker analyses
Peter Schmid et al.
CANCER RESEARCH (2017)
Granzyme B PET Imaging as a Predictive Biomarker of Immunotherapy Response
Benjamin M. Larimer et al.
CANCER RESEARCH (2017)
PD-L1 Detection in Tumors Using [64Cu]Atezolizumab with PET
Wojciech G. Lesniak et al.
BIOCONJUGATE CHEMISTRY (2016)
Checkpoint Inhibitors and Their Application in Breast Cancer
Davide Bedognetti et al.
BREAST CARE (2016)
Molecular Imaging of Immunotherapy Targets in Cancer
Emily B. Ehlerding et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
Weiping Zou et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors
Samit Chatterjee et al.
ONCOTARGET (2016)
High-Resolution PET Imaging with Therapeutic Antibody-based PD-1/PD-L1 Checkpoint Tracers
Michael Hettich et al.
THERANOSTICS (2016)
An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers
Giulia Bottai et al.
BREAST CANCER RESEARCH (2016)
Novel Radiotracer for ImmunoPET Imaging of PD-1 Checkpoint Expression on Tumor Infiltrating Lymphocytes
Arutselvan Natarajan et al.
BIOCONJUGATE CHEMISTRY (2015)
Noninvasive Imaging of Tumor PD-L1 Expression Using Radiolabeled Anti-PD-L1 Antibodies
Sandra Heskamp et al.
CANCER RESEARCH (2015)
Cancer Immunotherapy: A Future Paradigm Shift in the Treatment of Non-Small Cell Lung Cancer
Valsamo K. Anagnostou et al.
CLINICAL CANCER RESEARCH (2015)
Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma
Yuki Katsuya et al.
LUNG CANCER (2015)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging
Roy L. Maute et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway
Kim C. Ohaegbulam et al.
TRENDS IN MOLECULAR MEDICINE (2015)
T cell-NF-κB activation is required for tumor control in vivo
Sarah E. Barnes et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2015)
Perforin and granzymes: function, dysfunction and human pathology
Ilia Voskoboinik et al.
NATURE REVIEWS IMMUNOLOGY (2015)
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
Janis M. Taube et al.
CLINICAL CANCER RESEARCH (2014)
64Cu-DOTA-Anti-CTLA-4 mAb Enabled PET Visualization of CTLA-4 on the T-Cell Infiltrating Tumor Tissues
Kei Higashikawa et al.
PLOS ONE (2014)
Zirconium-89 Labeled Antibodies: A New Tool for Molecular Imaging in Cancer Patients
Floor C. J. van de Watering et al.
BIOMED RESEARCH INTERNATIONAL (2014)
PD-L1 Expression in Triple-Negative Breast Cancer
Elizabeth A. Mittendorf et al.
CANCER IMMUNOLOGY RESEARCH (2014)
The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer
S. Muenst et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non-Small-Cell Lung Cancer
David R. Spigel et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
New checkpoint inhibitors ride the immunotherapy tsunami
Asher Mullard
NATURE REVIEWS DRUG DISCOVERY (2013)
A MOLECULAR IMAGING PRIMER: MODALITIES, IMAGING AGENTS, AND APPLICATIONS
Michelle L. James et al.
PHYSIOLOGICAL REVIEWS (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Share Paper
